Opportunity Information: Apply for RFA CK 11 0010401SUPP14
Apply for RFA CK 11 0010401SUPP14
- The Centers for Disease Control and Prevention in the health sector is offering a public funding opportunity titled "Epi Centers for the Prevention of Healthcare Associated Infections, Antimicrobial Resistance and Adverse Events Multicenter Expansion of Current Investigation" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.084 Prevention of Disease, Disability, and Death by Infectious Diseases.
- This funding opportunity was created on Mar 19, 2014 and posted on Mar 14, 2014.
- Applicants must submit their applications by Apr 30, 2014. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $5,000,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $1,000,000.00 in funding.
- The number of recipients for this funding is limited to 5 candidate(s).
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification).
- 1.Eligible Applicants Eligible Organizations The following organizations are eligible to apply Harvard Pilgrim Healthcare, Inc. Duke University Washington University University of Pennsylvania Hektoen Institute for Medical Research 2. Foreign Organizations Foreign Organizations are not eligible to apply. Foreign components of U.S. Organizations are not eligible to apply. For this announcement, applicants may not include collaborators or consultants from foreign institutions. All applicable federal laws and policies apply. 3.Special Eligibility Requirements The research activities conducted under program announcement CK11 001 Epi Centers for the Prevention of Healthcare Associated Infections, Antimicrobial Resistance and Adverse Events has been established to develop, implement and evaluate the effectiveness of epidemiologically based strategies to improve healthcare quality and patient safety. The program is composed of two components 1) Investigator Initiated Projects designed to develop and test novel HAI prevention strategies, and 2) Prevention Research Emphasis Projects (PREPs), which include the development and implementation of additional HAI prevention research proposals that meet emerging or evolving public health research needs.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The grant opportunity titled "Epi Centers for the Prevention of Healthcare Associated Infections, Antimicrobial Resistance and Adverse Events Multicenter Expansion of Current Investigation" is a CDC cooperative agreement designed to strengthen and expand the work of the CDC Prevention Epicenters Program. The core purpose is to move promising infection prevention and patient safety approaches from earlier-stage findings into broader, real-world testing. In practice, this means translating basic scientific insights, epidemiologic evidence, and technology-driven tools into practical strategies that reduce healthcare-associated infections (HAIs), slow or prevent antimicrobial resistance (AR), and address other serious adverse events across a wide range of U.S. healthcare settings.
A defining feature of this opportunity is its emphasis on multicenter expansion. The CDC is looking to take prevention strategies that may have shown promise in single-center Epicenters studies and evaluate them across multiple sites, where patient populations, staffing models, facility resources, and baseline risks can differ substantially. That kind of multicenter work is critical in infection prevention because an intervention that works in one hospital, unit, or system may perform differently elsewhere. By supporting broader evaluation, the program aims to produce stronger evidence on effectiveness, feasibility, and implementation, with the end goal of improving healthcare quality and patient safety at scale.
This announcement is listed as a continuation opportunity, with funding delivered through a cooperative agreement rather than a standard grant. The cooperative agreement structure typically signals substantial involvement by the CDC in areas such as project coordination, alignment with public health priorities, and collaborative oversight during the study period. The activity category is health, and the CFDA listing is 93.084, identified as "Prevention of Disease, Disability, and Death by Infectious Diseases." There is no cost sharing or matching requirement, which reduces barriers for applicants and keeps the focus on project design, execution, and measurable outcomes.
Funding details indicate an estimated total program funding level of $5,000,000 with an expected five awards. Individual awards are projected to range from an award floor of $400,000 up to an award ceiling of $1,000,000. These levels suggest projects of meaningful scope, consistent with multicenter research that requires coordination across institutions, standardized data collection, and potentially complex implementation and evaluation plans. The opportunity was posted March 14, 2014, created March 19, 2014, and had an application deadline of April 30, 2014, with an archive date of May 30, 2014.
Eligibility is highly restricted and limited to a specified list of organizations associated with the Epicenters network for this continuation action. The eligible applicants named are Harvard Pilgrim Healthcare, Inc.; Duke University; Washington University; the University of Pennsylvania; and the Hektoen Institute for Medical Research. Foreign organizations are explicitly ineligible, and foreign components of U.S. organizations are also not eligible. In addition, applicants may not include collaborators or consultants from foreign institutions, reinforcing that all project activities and partnerships must remain domestic. This limitation reflects the program's focus on U.S. healthcare facilities and ensures compliance with applicable federal laws and policies.
The opportunity also sits within the broader structure of the Prevention Epicenters Program, which includes two major components: Investigator Initiated Projects and Prevention Research Emphasis Projects (PREPs). Investigator Initiated Projects are meant to develop and test new HAI prevention strategies, while PREPs are intended to address emerging or evolving public health research needs by supporting additional prevention research proposals aligned with current priorities. This multicenter expansion announcement fits that overall framework by encouraging further investigation of interventions that are already in the pipeline and appear ready for more rigorous, multi-site evaluation.
For applicants or stakeholders needing help accessing the full announcement, the contact point is the CDC Procurement and Grants Office, reachable by phone at 770-488-2700 or by email at pgotim@cdc.gov.
FAQs: Epi Centers for the Prevention of Healthcare Associated Infections, Antimicrobial Resistance and Adverse Events (Multicenter Expansion of Current Investigation)
What is the title of this grant opportunity?
The opportunity is titled "Epi Centers for the Prevention of Healthcare Associated Infections, Antimicrobial Resistance and Adverse Events Multicenter Expansion of Current Investigation."
Which federal agency is offering this opportunity?
This is a CDC (Centers for Disease Control and Prevention) cooperative agreement opportunity.
What is the main purpose of this funding?
The core purpose is to strengthen and expand the CDC Prevention Epicenters Program by moving promising infection prevention and patient safety approaches from earlier-stage findings into broader, real-world testing across multiple sites.
What kinds of problems is this program trying to address?
The program focuses on reducing healthcare-associated infections (HAIs), slowing or preventing antimicrobial resistance (AR), and addressing other serious adverse events in U.S. healthcare settings.
What does "multicenter expansion" mean in this announcement?
Multicenter expansion means taking prevention strategies that showed promise in single-center Epicenters studies and evaluating them across multiple sites. This helps determine whether interventions remain effective and feasible when implemented in different facilities with different patient populations, staffing models, resources, and baseline risks.
Why does the CDC emphasize multicenter evaluation for infection prevention?
Because an intervention that works in one hospital, unit, or system may perform differently elsewhere. Multicenter evaluation is intended to produce stronger evidence on effectiveness, feasibility, and implementation across varied real-world settings, supporting improvement of healthcare quality and patient safety at scale.
Is this a standard grant or something else?
It is a cooperative agreement rather than a standard grant.
What does a cooperative agreement imply for how the project will be run?
The cooperative agreement structure typically signals substantial CDC involvement, such as project coordination, alignment with public health priorities, and collaborative oversight during the study period.
Is this a new opportunity or a continuation?
This announcement is listed as a continuation opportunity.
What is the activity category for this opportunity?
The activity category is health.
What is the CFDA number and program name associated with this funding?
The CFDA listing is 93.084, identified as "Prevention of Disease, Disability, and Death by Infectious Diseases."
Is cost sharing or matching required?
No. There is no cost sharing or matching requirement.
How much total funding is expected under this program?
The estimated total program funding level is $5,000,000.
How many awards does the CDC expect to make?
The CDC expects to make five awards.
What is the expected funding range per award?
Individual awards are projected to range from an award floor of $400,000 to an award ceiling of $1,000,000.
What types of projects do these award sizes suggest?
The projected funding levels suggest projects of meaningful scope, consistent with multicenter research that may require coordination across institutions, standardized data collection, and complex implementation and evaluation plans.
When was the opportunity posted and created?
The opportunity was posted March 14, 2014, and created March 19, 2014.
What was the application deadline?
The application deadline was April 30, 2014.
When was the opportunity archived?
The archive date was May 30, 2014.
Who is eligible to apply?
Eligibility is highly restricted for this continuation action and limited to the specified organizations associated with the Epicenters network: Harvard Pilgrim Healthcare, Inc.; Duke University; Washington University; the University of Pennsylvania; and the Hektoen Institute for Medical Research.
Are foreign organizations eligible to apply?
No. Foreign organizations are explicitly ineligible.
Are foreign components of U.S. organizations allowed?
No. Foreign components of U.S. organizations are also not eligible.
Can applicants include collaborators or consultants from foreign institutions?
No. Applicants may not include collaborators or consultants from foreign institutions. Project activities and partnerships must remain domestic.
Why does the announcement restrict foreign involvement?
The restriction reflects the program's focus on U.S. healthcare facilities and is intended to ensure compliance with applicable federal laws and policies.
How does this announcement fit within the broader CDC Prevention Epicenters Program?
The Prevention Epicenters Program includes two major components: Investigator Initiated Projects and Prevention Research Emphasis Projects (PREPs). This multicenter expansion announcement aligns with that overall framework by encouraging further investigation of interventions that are already in the pipeline and appear ready for more rigorous, multi-site evaluation.
What are Investigator Initiated Projects within the Epicenters Program?
Investigator Initiated Projects are meant to develop and test new HAI prevention strategies.
What are Prevention Research Emphasis Projects (PREPs)?
PREPs are intended to address emerging or evolving public health research needs by supporting additional prevention research proposals aligned with current priorities.
What is the practical goal of translating earlier-stage findings into real-world testing?
The goal is to translate basic scientific insights, epidemiologic evidence, and technology-driven tools into practical strategies that reduce HAIs, slow or prevent AR, and improve patient safety outcomes across a wide range of U.S. healthcare settings.
Who should be contacted for help accessing the full announcement?
Contact the CDC Procurement and Grants Office.
What are the contact details for the CDC Procurement and Grants Office?
Phone: 770-488-2700. Email: pgotim@cdc.gov.
Browse more opportunities from the same agency: Centers for Disease Control and Prevention
Browse more opportunities from the same category: Health
Next opportunity: Natural Resource Condition Assessment for National Park of American Samoa
Previous opportunity: LIMNOLOGICAL AND RIPARIAN RESOURCE CONDITION ASSESSMENT AT LAKE MEAD NATIONAL RECREATION AREA
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA CK 11 0010401SUPP14
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA CK 11 0010401SUPP14) also looked into and applied for these:
| Funding Opportunity |
|---|
| PPHF 2014 Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) Building and Strengthening Epidemiology, Laboratory and Health Information Systems Capacity in State and Local Health Departments financed in part by 2014 Prevention and P Apply for CDC RFA CK14 1401PPHF14 Funding Number: CDC RFA CK14 1401PPHF14 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Creutzfeldt Jakob Disease (CJD) Increasing Educational Apply for CDC RFA CK10 100105CONT14 Funding Number: CDC RFA CK10 100105CONT14 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Continuing Enhanced National Surveillance for Prion Diseases in the United States Apply for CDC RFA CK12 120803CONT14 Funding Number: CDC RFA CK12 120803CONT14 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Hospital Preparedness Program (HPP) and Public Health Emergency Preparedness (PHEP) Cooperative Agreements Apply for CDC RFA TP12 120102CONT14 Funding Number: CDC RFA TP12 120102CONT14 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Building Capacity of the Public Health System to Improve Population Health through National, Nonprofit Organizations Apply for CDC RFA OT13 130202CONT14 Funding Number: CDC RFA OT13 130202CONT14 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Serve as the U.S. partner within the global STOP TB Partnership and participate in Stop TB Partnership activities Apply for CDC RFA PS12 120803CONT14 Funding Number: CDC RFA PS12 120803CONT14 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| BioSense 2.0 Building State, Local, Tribal, and Territorial Surveillance Capacity to Enhance Regional and National All Hazards Public Health Situation Awareness Center for Surveillance, Epidemiology and Laboratory Services Apply for CDC RFA OE12 120203CONT14 Funding Number: CDC RFA OE12 120203CONT14 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Family Planning, Maternal, Neonatal and Child Health (FP/MNCH) Project in Afghanistan Apply for SOL 306 14 00226 Funding Number: SOL 306 14 00226 Agency: Afghanistan USAID Kabul Category: Health Funding Amount: $55,000,000 |
| Global Non Communicable Disease Prevention and Promotion of Health Apply for CDC RFA GH14 1420 Funding Number: CDC RFA GH14 1420 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Human Immunodeficiency Virus (HIV) Prevention Projects for Young Men of Color Who Have Sex with Men (YMSM of Color) and Apply for CDC RFA PS11 111304CONT14 Funding Number: CDC RFA PS11 111304CONT14 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Atopic Dermatitis Research Network (ADRN) (U19) Apply for RFA AI 14 033 Funding Number: RFA AI 14 033 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Translational Research to Help Older Adults Maintain their Health and Independence in the Community (R21) Apply for PA 14 159 Funding Number: PA 14 159 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Translational Research to Help Older Adults Maintain their Health and Independence in the Community (R01) Apply for PA 14 161 Funding Number: PA 14 161 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Girls Education Strengthen Family and Community Support to Orphans and Vulnerable Children Program Apply for RFA 656 14 000001 Funding Number: RFA 656 14 000001 Agency: Mozambique USAID Maputo Category: Health Funding Amount: $15,864,752 |
| Population based HIV Impact Assessments in Resource Constrained Settings under the Presidents Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH14 1409 Funding Number: CDC RFA GH14 1409 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $25,000,000 |
| Rural Access to Emergency Devices Grant Program Apply for HRSA 14 129 Funding Number: HRSA 14 129 Agency: Health Resources and Services Administration Category: Health Funding Amount: $150,000 |
| Public Access to Defibrillation Demonstration Project Apply for HRSA 14 130 Funding Number: HRSA 14 130 Agency: Health Resources and Services Administration Category: Health Funding Amount: $150,000 |
| Mali High Impact Health Services II Apply for RFA 688 14 000005 Funding Number: RFA 688 14 000005 Agency: Mali USAID Bamako Category: Health Funding Amount: $45,000,000 |
| Accelerating Medicines Partnership (AMP) in Rheumatoid Arthritis and Lupus Network Leadership Center (UM2) Apply for RFA AR 14 015 Funding Number: RFA AR 14 015 Agency: National Institutes of Health Category: Health Funding Amount: $2,000,000 |
| Accelerating Medicines Partnership (AMP) in Rheumatoid Arthritis and Lupus Network Research Sites (UH2/UH3) Apply for RFA AR 14 016 Funding Number: RFA AR 14 016 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA CK 11 0010401SUPP14", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.